|Dr. Joshua Michael Hare FACC, M.D.||Co-Founder, Chief Science Officer & Chairman||449.81k||N/A||1963|
|Mr. James Clavijo CPA||CFO & Treasurer||481.07k||N/A||1966|
|Mr. Paul T. Lehr J.D.||International Exec. Director, Gen. Counsel & Sec.||465.25k||N/A||1968|
|Dr. Kwan-Hong Min M.D., Ph.D.||Chief Medical Officer & Interim CEO||N/A||N/A||1967|
|Dr. Dan Gincel Ph.D.||Sr. VP of Strategic Collaborations & Scientific Affairs||N/A||N/A||1971|
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.